Therapy Overview & Search
This is the search page for all therapy, you can search for name or condition
Filter By
Therapeutic Area
Manufacturer
SORT BY
-
Fosrenol (lanthanum carbonate)
Fosrenol (lanthanum carbonate) is a lanthanum salt that binds to phosphous in the GI tract to prevent its absorption and to lower its levels in the blood.Manufacturer:Misc.Route of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormConditions:
- Hyperphosphatemia
- Chronic Kidney Disease
Therapeutic Area:
- Endocrinology
- Nephrology
-
Fulphila (pegfilgrastim-jmdb)
Fulphila (pegfilgrastim-jmdb) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fulphila is a leukocyte growth factor that stimulates blood cell production.Manufacturer:Biocon BiologicsRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-833-695-2623Approved Indication:
to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Therapeutic Area:
- Oncology
-
Fylnetra (pegfilgrastim-pbbk)
Fylnetra (pegfilgrastim-pbbk) is an FDA-approved biosimilar to Neulasta. Like Neulasta, Fylnetra is a leukocyte growth factor that stimulates blood cell production.Manufacturer:Amneal PharmaceuticalsRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:866-4AMNEAL (866-426-6325)Approved Indication:
- to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of febrile neutropenia
- to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
- Hematopoietic Syndrome of Acute Radiation Syndrome
Therapeutic Area:
- Oncology
-
Gengraf (cyclosporine, modified)
Gengraf (cyclosporine, modified) inhibits the enzyme calcineurin to decrease immune responsiveness and prevent rejection of a transplanted organ.Manufacturer:Misc.Route of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- prophylaxis of organ rejection in kidney, liver, and heart allogenic transplants
- treatment of patients with severe, active rheumatoid arthritis where the disease has not adequately responded to methotrexate
- treatment of adult, nonimmunocompromised patients with severe, recalcitrant plaque psoriasis who have failed to respond to at least one systemic therapy or for whom other systemic therapies are contraindicated or cannot be tolerated
Conditions:
- Solid Organ Transplant
- Rheumatoid Arthritis
- Plaque Psoriasis
Therapeutic Area:
- Cardiology
- Dermatology
- Hepatology
- Nephrology
- Rheumatology
- Transplant
-
Gimoti (metoclopramide)
Gimoti (metoclopramide) is a nasal spray FDA-approved to improve GI motility in diabetic patients with gastroparesis.Manufacturer:Evoke PharmaRoute of Administration:IntranasalSite of Care:OutpatientWebsite:Enrollment Forms:Patient Support FormApproved Indication:
relief of symptoms in adults with acute and recurrent diabetic gastroparesis
Conditions:
- Gastroparesis
Therapeutic Area:
- Gastroenterology
-
Granix (tbo-filgrastim)
Granix (tbo-filgrastim) is a colony-stimulating factor that increases circulating levels of neutrophils, a type of white blood cell.Manufacturer:TevaRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:Approved Indication:
for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia in adult and pediatric patients 1 month and older
Conditions:
- Neutropenia Associated with Myelosuppressive Anti-Cancer Therapy
Therapeutic Area:
- Oncology
-
Hadlima (adalimumab-bwwd)
Hadlima (adalimumab-bwwd) is an FDA-approved biosimilar to Humira. Like Humira, Hadlima is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:OrganonRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-855-460-7928Approved Indication:
-
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adult patients
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in adult patients
- treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
-
Harvoni (ledipasvir/sofosbuvir)
Harvoni (ledipasvir/sofosbuvir) is a combination of two antiviral medications approved to treat chronic hepatitis C infections in patients with hepatitis C genotypes 1, 4, 5, or 6 regardless of concomitant cirrhosis.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older with either
- genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis
- genotype 1 with decompensated cirrhosis in combination with ribavirin
- genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis in combination with ribavirin
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease
-
Hulio (adalimumab-fkjp)
Hulio (adalimumab-fkjp) is an FDA-approved, citrate-free, interchangeable biosimilar to Humira. Like Humira, Hulio is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:OrganonRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-855-460-7928Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adult patients
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in adult patients
- treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Humira (adalimumab)
Humira (adalimumab) is the original, or “reference,” adalimumab product. Adalimumab is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:AbbVieRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:phone:1-800-488-6472Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
- treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology
-
Hydrea (hydroxyurea)
Hydrea (hydroxyurea) is an antimetabolite that slows down cell growth. In sickle cell diease, it is approved to reduce the number of painful crises and the need for blood transfusions.Manufacturer:Bristol Myers SquibbRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
- treatment of locally advanced squamous cell carcinomas of the head and neck, (excluding lip) in combination with concurrent chemoradiation
Conditions:
- Chronic Myeloid Leukemia
- Squamous Cell Carcinoma
- Sickle Cell Disease
Therapeutic Area:
- Oncology
-
Hyrimoz (adalimumab-adaz)
Hyrimoz (adalimumab-adaz) is an FDA-approved biosimilar to Humira. Like Humira, Hyrimoz is a monoclonal antibody that blocks the action of TNF-alpha to reduce inflammation in rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and panuveitis.Manufacturer:SandozRoute of Administration:SubcutaneousSite of Care:OutpatientWebsite:Approved Indication:
- reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
- reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
- reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
- reducing signs and symptoms in adult patients with active ankylosing spondylitis
- treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
- treatment of moderately to severely active ulcerative colitis in adults and pediatric patients 5 years of age and older
- treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
- treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older
- treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older
Conditions:
- Ankylosing Spondylitis
- Crohn’s Disease
- Hidradenitis Suppurativa
- Juvenile Idiopathic Arthritis
- Plaque Psoriasis
- Psoriatic Arthritis
- Rheumatoid Arthritis
- Ulcerative Colitis
- Uveitis
Therapeutic Area:
- Dermatology
- Gastroenterology
- Rheumatology